Spots Global Cancer Trial Database for Postoperative Analgesic Effect of Subcostal TAPB for Laparoscopic Gastrectomy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Postoperative Analgesic Effect of Subcostal TAPB for Laparoscopic Gastrectomy

Official Title: Ultrasound-guided Subcostal Transversus Abdominis Plane Block in Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy: A Randomized Controlled Double-blinded Study

Study ID: NCT04138901

Conditions

Postoperative Pain

Interventions

Ultrasound guided subcostal transversus abdominis plane block (TAPB)

Ropivacaine 0.75% Injectable Solution

21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)

Study Description

Brief Summary: This prospective, randomized, single blinded study is designed to evaluate the postoperative analgesic efficacy of the ultrasound-guided subcostal transversus abdominis plane block in gastric cancer patients undergoing laparoscopic gastrectomy. We hypothesize that US guided subcostal TAP block with ropivacaine can significantly reduce postoperative opioid comparison in patients with laparoscopic gastrectomy.

Detailed Description: Adult patients undergoing elective laparoscopic gastrectomy are randomly allocated to receive subcostal TAP block (n=56) or not (n=56), in addition to a standard postoperative analgesic regimen comprising of IV fentanyl-based patient-controlled analgesia (PCA) and NSAIDs as required. At the end of surgery, the TAP group patients will receive bilateral subcostal TAP block under ultrasound guidance with 15ml of 0.375% ropivacaine bilaterally. Each patient was assessed by a blinded investigator at 6, 12, 24, and 48 h postoperatively. The primary outcome is total fentanyl consumption at 24 h after surgery.